BACKGROUND The degree of antiplatelet response to clopidogrel has been associated with clinical outcomes. Studies
T reatment with aspirin and clopidogrel after percutaneous coronary intervention (PCI) is frequently used to prevent ischemic complications, including stent thrombosis (1) , and this approach has been shown to reduce cardiovascular events in patients with acute coronary syndromes (ACS) (2) . Studies have demonstrated variability in the pharmacodynamic response to clopidogrel (3, 4) . This variability can be explained in part by genetic polymorphisms (5) , as well as by demographic, cellular, and clinical factors (6) (7) (8) (9) . Some clinical studies have demonstrated that patients with high on-clopidogrel platelet reactivity are at increased risk of stent thrombosis and other major cardiac complications (10) (11) (12) .
Further studies have investigated whether dose adjustment of clopidogrel can overcome this high on-treatment platelet reactivity (13) (14) (15) (16) 
RESULTS
The mean age in the study population was 60.2 AE 9.9 years, 75% were male, 57% had a history of myocardial infarction, and 97% had a history of PCI. When assessing patients with serial measurements, the mean platelet reactivity as determined by the VerifyNow P2Y 12 test and VASP assays did not differ between serial sampling with the 75-mg and 150-mg doses of clopidogrel (Table 1) . Likewise, the total proportion of nonresponders to clopidogrel did not change between both periods at the same dose of clopidogrel ( Table 1) .
In contrast, analyzing each patient individually, (Fig. 1) . The number of patients changing from responder to nonresponder status was similar to the number of patients switching in the opposite direction.
Because even a minor change in platelet reactivity could alter the responder status (i.e., from 229 PRU to 230 PRU), data were also analyzed in a continuous fashion. The individual change in platelet reactivity over time approximated a Gaussian distribution with equal changes in both directions being found (Fig. 2) . Notably, the SDs for the change in platelet Table A) . Values are n (%).
Abbreviation as in Table 1 . Hochholzer et al. Values are % (95% confidence interval).
Abbreviations as in Table 1 .
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